A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Saved in:
| Title: | A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice. |
|---|---|
| Authors: | Fisher TS; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA. timothy.s.fisher@pfizer.com.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA. timothy.s.fisher@pfizer.com.; Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA. timothy.s.fisher@pfizer.com., Hooper AT; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Lucas J; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Clark TH; BioMedicine Design Pfizer Inc., Cambridge, MA, USA., Rohner AK; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Peano B; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Elliott MW; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Tsaparikos K; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Wang H; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Golas J; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Gavriil M; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Haddish-Berhane N; BioMedicine Design Pfizer Inc., Cambridge, MA, USA.; Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA, USA., Tchistiakova L; BioMedicine Design Pfizer Inc., Cambridge, MA, USA., Gerber HP; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.; Maverick Therapeutics, Brisbane, CA, USA., Root AR; BioMedicine Design Pfizer Inc., Cambridge, MA, USA., May C; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.; Maverick Therapeutics, Brisbane, CA, USA. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2018 Feb; Vol. 67 (2), pp. 247-259. Date of Electronic Publication: 2017 Oct 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-017-2081-0 |
